Barely Significant
← all excerpts

Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort.

Dermatol Ther (Heidelb) · 2026 · PMC12936218 · PMID 41491444

Europe PMCDOI
1
hedged sentence
0.0510
closest p · 1.0× alpha
0.0510
boldest claim

The sentences

borderline significantp = 0.051so close (0.05 < p ≤ 0.1)
In the systemic JAKi group, the overall rate of adverse events tended to be higher in ineligible patients compared with eligible ones, although this difference was only borderline significant ( p = 0.051).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.